TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics Limited announced the cessation of 5,626,000 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future growth prospects.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic drugs. The company is engaged in creating innovative treatments aimed at addressing unmet medical needs, with a particular emphasis on cancer therapies.
Average Trading Volume: 3,754,086
Technical Sentiment Signal: Buy
Current Market Cap: A$89.79M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.